TY  - GEN
AU  - García-Saenz, José A
AU  - Spera, Gonzalo
AU  - Pollan-Santamaria, Marina
AU  - Bermejo, Begoña
AU  - Ruiz-Borrego, Manuel
AU  - Chan, Arlene
AU  - Martín, Miguel
AU  - Guerrero-Zotano, Ángel
AU  - Calvo, Lourdes
AU  - Rodríguez-Lescure, Álvaro
AU  - Marín, María
AU  - Chap, Linnea
AU  - Crown, John
AU  - Pienkowski, Tadeusz
AU  - Bee, Valerie
AU  - Casas, Maribel
AU  - Polonio, Óscar
AU  - Bezares, Susana
AU  - Slamon, Dennis
PY  - 2025
DO  - 10.1002/ijc.35432
UR  - https://hdl.handle.net/20.500.12105/27660
AB  - Adjuvant anthracyclines and taxanes reduce recurrence and death in early-stage breast cancer (EBC) patients, but toxicity is a concern. Studies show conflicting results on the correlation between body mass index (BMI) and outcomes. Limited data exist...
LA  - eng
PB  - Wiley
KW  - Body mass index
KW  - Docetaxel
KW  - Early‐stage breast cancer
KW  - Paclitaxel
KW  - Pooled analysis
KW  - Survival
KW  - Adult
KW  - Aged
KW  - Anthracyclines
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Body Mass Index
KW  - Breast Neoplasms
KW  - Chemotherapy, Adjuvant
KW  - Docetaxel
KW  - Female
KW  - Humans
KW  - Middle Aged
KW  - Neoplasm Staging
KW  - Obesity
KW  - Paclitaxel
KW  - Prognosis
KW  - Taxoids
KW  - Treatment Outcome
TI  - Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies.
TY  - research article
ER  -